Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Says it plans to initiate a Phase 1 study in polycythaemia vera with SLN124, the third indication being assessed using endogenous hepcidin modulation. Says SLN360 single-ascending dose study on-track for topline data in first-quarter 2022 - independent review committee recommends extending follow-up period to assess potential longer duration of action.
President & Chief Executive Officer Mark Rothera says: "We are pleased to report strong progress across both our proprietary and partnered pipelines, including plans to further expand the SLN124 program into a third indication, PV, where endogenous hepcidin modulation can potentially improve outcomes for 3.5 million people worldwide who currently have very limited treatment options. Through our hybrid business model, we are committed to maximizing the substantial opportunity for our mRNAi GOLD platform and remain well positioned to deliver 2-3 INDs per year from 2023."
Current stock price: 512.00 pence
Year-to-date change: down 0.8%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
